Global Nano-drug

Nano-drug Comprehensive Study by Type (Nanoparticles (Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles), Nanoshells, Nanotubes, Nanodevices), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, Other), Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles, Others), Product Type (Therapeutics, Regenerative medicine, In-vitro diagnostics, In-vivo diagnostics, Vaccines) Players and Region - Global Market Outlook to 2030

Nano-drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 12.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Nano-drug Market Scope?
Nanoscale technology is at present very widely used in medicine, wherein the manipulations are carried out at the molecular level, thereby taking advantage of the novel properties of a material. The main requirement of this area of medicine is to improve treatment delivery and health outcomes. Nanotechnology drug delivery is the use of nanoscale materials and technologies for healthcare in drug delivery to improve the effectiveness of the drug. Nano drugs are a revolutionary and ubiquitous science of the 21st century; a nano-drug is the application of nanotechnology in the medical field, which has the potential to significantly change the course of the diagnosis and treatment of various life-threatening diseases. A nano-drug is basically the application of nanotechnology to medicines, and they are thought to have a huge impact on public health. The interest in nanopharmaceuticals for treatment and diagnosis is clearly reflected in a large number of high-quality research publications and patents that are granted each year. It also sheds light on the current scale-up, market size, and application of nano drugs, including future challenges.

Influencing Trend:
Growing Preference for Personalized Medicines and Development of Novel Nanotechnology-Based Drugs and Therapies

Market Growth Drivers:
Increasing Prevalence of Chronic Diseases and Illnesses and A Rise in the Diagnosis and Monitoring of the Effects of Drugs on an Unprecedented Short Timescale

Challenges:
The Cost of Nanotechnology Drug Delivery Medicine

Restraints:
Stringent Regulations for the Mechanism Approval

Opportunities:
Increasing Advancements in Nanoscale Technologies and The Growing Need To Develop Therapies That Have Fewer Side Effects and That Are More Cost-Effective Than Traditional Therapies

The Nano-drug market study is being classified by Type (Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles], Nanoshells, Nanotubes and Nanodevices), by Application and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Nano-drug market throughout the predicted period.

Merck & Co. (United States), Pfizer (United States), Novartis (Switzerland), Abbott Laboratories (United States), GlaxoSmithKline (United Kingdom), Roche Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Celgene (United States), Novavax (United States), Stryker Corporation (United States), Gilead Sciences (United States), Samyang Biopharm (South Korea), Kaken Pharmaceutical (Japan), Selecta Biosciences (United States) and Par Pharmaceutical, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cerulean Pharma, Inc. (United States), Navidea Biopharmaceuticals, Inc. (United States) and Chongqing LUMMY Pharmaceutical Co., Ltd. (China).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Nano-drug market by Type, Application and Region.

On the basis of geography, the market of Nano-drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In November 2015, Ablynx and Novo Nordisk signed a global collaboration and license agreement for the development and discovery of innovative drugs with multispecific nanobodies. This strategic partnership is expected to increase net annual sales of the products and drive market growth.



Key Target Audience
Providers of Nano-drug, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Nano-drug Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Nano-drug Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Nano-drug industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
  • Nanoshells
  • Nanotubes
  • Nanodevices
By Application
  • Neurology
  • Oncology
  • Cardiovascular/Physiology
  • Anti-inflammatory/Immunology
  • Anti-infective
  • Other
By Technology
  • Nanocrystals
  • Nanoparticles
  • Liposomes
  • Micelles
  • Others

By Product Type
  • Therapeutics
  • Regenerative medicine
  • In-vitro diagnostics
  • In-vivo diagnostics
  • Vaccines

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Diseases and Illnesses
      • 3.2.2. A Rise in the Diagnosis and Monitoring of the Effects of Drugs on an Unprecedented Short Timescale
    • 3.3. Market Challenges
      • 3.3.1. The Cost of Nanotechnology Drug Delivery Medicine
    • 3.4. Market Trends
      • 3.4.1. Growing Preference for Personalized Medicines
      • 3.4.2. Development of Novel Nanotechnology-Based Drugs and Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nano-drug, by Type, Application, Technology, Product Type and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nano-drug (Value)
      • 5.2.1. Global Nano-drug by: Type (Value)
        • 5.2.1.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 5.2.1.2. Nanoshells
        • 5.2.1.3. Nanotubes
        • 5.2.1.4. Nanodevices
      • 5.2.2. Global Nano-drug by: Application (Value)
        • 5.2.2.1. Neurology
        • 5.2.2.2. Oncology
        • 5.2.2.3. Cardiovascular/Physiology
        • 5.2.2.4. Anti-inflammatory/Immunology
        • 5.2.2.5. Anti-infective
        • 5.2.2.6. Other
      • 5.2.3. Global Nano-drug by: Technology (Value)
        • 5.2.3.1. Nanocrystals
        • 5.2.3.2. Nanoparticles
        • 5.2.3.3. Liposomes
        • 5.2.3.4. Micelles
        • 5.2.3.5. Others
      • 5.2.4. Global Nano-drug by: Type (Value)
        • 5.2.4.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 5.2.4.2. Nanoshells
        • 5.2.4.3. Nanotubes
        • 5.2.4.4. Nanodevices
      • 5.2.5. Global Nano-drug by: Product Type (Value)
        • 5.2.5.1. Therapeutics
        • 5.2.5.2. Regenerative medicine
        • 5.2.5.3. In-vitro diagnostics
        • 5.2.5.4. In-vivo diagnostics
        • 5.2.5.5. Vaccines
      • 5.2.6. Global Nano-drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Nano-drug (Volume)
      • 5.3.1. Global Nano-drug by: Type (Volume)
        • 5.3.1.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 5.3.1.2. Nanoshells
        • 5.3.1.3. Nanotubes
        • 5.3.1.4. Nanodevices
      • 5.3.2. Global Nano-drug by: Application (Volume)
        • 5.3.2.1. Neurology
        • 5.3.2.2. Oncology
        • 5.3.2.3. Cardiovascular/Physiology
        • 5.3.2.4. Anti-inflammatory/Immunology
        • 5.3.2.5. Anti-infective
        • 5.3.2.6. Other
      • 5.3.3. Global Nano-drug by: Technology (Volume)
        • 5.3.3.1. Nanocrystals
        • 5.3.3.2. Nanoparticles
        • 5.3.3.3. Liposomes
        • 5.3.3.4. Micelles
        • 5.3.3.5. Others
      • 5.3.4. Global Nano-drug by: Type (Volume)
        • 5.3.4.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 5.3.4.2. Nanoshells
        • 5.3.4.3. Nanotubes
        • 5.3.4.4. Nanodevices
      • 5.3.5. Global Nano-drug by: Product Type (Volume)
        • 5.3.5.1. Therapeutics
        • 5.3.5.2. Regenerative medicine
        • 5.3.5.3. In-vitro diagnostics
        • 5.3.5.4. In-vivo diagnostics
        • 5.3.5.5. Vaccines
      • 5.3.6. Global Nano-drug Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Nano-drug (Price)
      • 5.4.1. Global Nano-drug by: Type (Price)
  • 6. Nano-drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Celgene (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novavax (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Stryker Corporation (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Gilead Sciences (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Samyang Biopharm (South Korea)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Kaken Pharmaceutical (Japan)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Selecta Biosciences (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Par Pharmaceutical, Inc. (United States)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Nano-drug Sale, by Type, Application, Technology, Product Type and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nano-drug (Value)
      • 7.2.1. Global Nano-drug by: Type (Value)
        • 7.2.1.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 7.2.1.2. Nanoshells
        • 7.2.1.3. Nanotubes
        • 7.2.1.4. Nanodevices
      • 7.2.2. Global Nano-drug by: Application (Value)
        • 7.2.2.1. Neurology
        • 7.2.2.2. Oncology
        • 7.2.2.3. Cardiovascular/Physiology
        • 7.2.2.4. Anti-inflammatory/Immunology
        • 7.2.2.5. Anti-infective
        • 7.2.2.6. Other
      • 7.2.3. Global Nano-drug by: Technology (Value)
        • 7.2.3.1. Nanocrystals
        • 7.2.3.2. Nanoparticles
        • 7.2.3.3. Liposomes
        • 7.2.3.4. Micelles
        • 7.2.3.5. Others
      • 7.2.4. Global Nano-drug by: Type (Value)
        • 7.2.4.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 7.2.4.2. Nanoshells
        • 7.2.4.3. Nanotubes
        • 7.2.4.4. Nanodevices
      • 7.2.5. Global Nano-drug by: Product Type (Value)
        • 7.2.5.1. Therapeutics
        • 7.2.5.2. Regenerative medicine
        • 7.2.5.3. In-vitro diagnostics
        • 7.2.5.4. In-vivo diagnostics
        • 7.2.5.5. Vaccines
      • 7.2.6. Global Nano-drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Nano-drug (Volume)
      • 7.3.1. Global Nano-drug by: Type (Volume)
        • 7.3.1.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 7.3.1.2. Nanoshells
        • 7.3.1.3. Nanotubes
        • 7.3.1.4. Nanodevices
      • 7.3.2. Global Nano-drug by: Application (Volume)
        • 7.3.2.1. Neurology
        • 7.3.2.2. Oncology
        • 7.3.2.3. Cardiovascular/Physiology
        • 7.3.2.4. Anti-inflammatory/Immunology
        • 7.3.2.5. Anti-infective
        • 7.3.2.6. Other
      • 7.3.3. Global Nano-drug by: Technology (Volume)
        • 7.3.3.1. Nanocrystals
        • 7.3.3.2. Nanoparticles
        • 7.3.3.3. Liposomes
        • 7.3.3.4. Micelles
        • 7.3.3.5. Others
      • 7.3.4. Global Nano-drug by: Type (Volume)
        • 7.3.4.1. Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles]
        • 7.3.4.2. Nanoshells
        • 7.3.4.3. Nanotubes
        • 7.3.4.4. Nanodevices
      • 7.3.5. Global Nano-drug by: Product Type (Volume)
        • 7.3.5.1. Therapeutics
        • 7.3.5.2. Regenerative medicine
        • 7.3.5.3. In-vitro diagnostics
        • 7.3.5.4. In-vivo diagnostics
        • 7.3.5.5. Vaccines
      • 7.3.6. Global Nano-drug Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Nano-drug (Price)
      • 7.4.1. Global Nano-drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nano-drug: by Type(USD Million)
  • Table 2. Nano-drug Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region USD Million (2018-2023)
  • Table 3. Nano-drug Nanoshells , by Region USD Million (2018-2023)
  • Table 4. Nano-drug Nanotubes , by Region USD Million (2018-2023)
  • Table 5. Nano-drug Nanodevices , by Region USD Million (2018-2023)
  • Table 6. Nano-drug: by Application(USD Million)
  • Table 7. Nano-drug Neurology , by Region USD Million (2018-2023)
  • Table 8. Nano-drug Oncology , by Region USD Million (2018-2023)
  • Table 9. Nano-drug Cardiovascular/Physiology , by Region USD Million (2018-2023)
  • Table 10. Nano-drug Anti-inflammatory/Immunology , by Region USD Million (2018-2023)
  • Table 11. Nano-drug Anti-infective , by Region USD Million (2018-2023)
  • Table 12. Nano-drug Other , by Region USD Million (2018-2023)
  • Table 13. Nano-drug: by Technology(USD Million)
  • Table 14. Nano-drug Nanocrystals , by Region USD Million (2018-2023)
  • Table 15. Nano-drug Nanoparticles , by Region USD Million (2018-2023)
  • Table 16. Nano-drug Liposomes , by Region USD Million (2018-2023)
  • Table 17. Nano-drug Micelles , by Region USD Million (2018-2023)
  • Table 18. Nano-drug Others , by Region USD Million (2018-2023)
  • Table 19. Nano-drug: by Type(USD Million)
  • Table 20. Nano-drug Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region USD Million (2018-2023)
  • Table 21. Nano-drug Nanoshells , by Region USD Million (2018-2023)
  • Table 22. Nano-drug Nanotubes , by Region USD Million (2018-2023)
  • Table 23. Nano-drug Nanodevices , by Region USD Million (2018-2023)
  • Table 24. Nano-drug: by Product Type(USD Million)
  • Table 25. Nano-drug Therapeutics , by Region USD Million (2018-2023)
  • Table 26. Nano-drug Regenerative medicine , by Region USD Million (2018-2023)
  • Table 27. Nano-drug In-vitro diagnostics , by Region USD Million (2018-2023)
  • Table 28. Nano-drug In-vivo diagnostics , by Region USD Million (2018-2023)
  • Table 29. Nano-drug Vaccines , by Region USD Million (2018-2023)
  • Table 30. South America Nano-drug, by Country USD Million (2018-2023)
  • Table 31. South America Nano-drug, by Type USD Million (2018-2023)
  • Table 32. South America Nano-drug, by Application USD Million (2018-2023)
  • Table 33. South America Nano-drug, by Technology USD Million (2018-2023)
  • Table 34. South America Nano-drug, by Product Type USD Million (2018-2023)
  • Table 35. Brazil Nano-drug, by Type USD Million (2018-2023)
  • Table 36. Brazil Nano-drug, by Application USD Million (2018-2023)
  • Table 37. Brazil Nano-drug, by Technology USD Million (2018-2023)
  • Table 38. Brazil Nano-drug, by Product Type USD Million (2018-2023)
  • Table 39. Argentina Nano-drug, by Type USD Million (2018-2023)
  • Table 40. Argentina Nano-drug, by Application USD Million (2018-2023)
  • Table 41. Argentina Nano-drug, by Technology USD Million (2018-2023)
  • Table 42. Argentina Nano-drug, by Product Type USD Million (2018-2023)
  • Table 43. Rest of South America Nano-drug, by Type USD Million (2018-2023)
  • Table 44. Rest of South America Nano-drug, by Application USD Million (2018-2023)
  • Table 45. Rest of South America Nano-drug, by Technology USD Million (2018-2023)
  • Table 46. Rest of South America Nano-drug, by Product Type USD Million (2018-2023)
  • Table 47. Asia Pacific Nano-drug, by Country USD Million (2018-2023)
  • Table 48. Asia Pacific Nano-drug, by Type USD Million (2018-2023)
  • Table 49. Asia Pacific Nano-drug, by Application USD Million (2018-2023)
  • Table 50. Asia Pacific Nano-drug, by Technology USD Million (2018-2023)
  • Table 51. Asia Pacific Nano-drug, by Product Type USD Million (2018-2023)
  • Table 52. China Nano-drug, by Type USD Million (2018-2023)
  • Table 53. China Nano-drug, by Application USD Million (2018-2023)
  • Table 54. China Nano-drug, by Technology USD Million (2018-2023)
  • Table 55. China Nano-drug, by Product Type USD Million (2018-2023)
  • Table 56. Japan Nano-drug, by Type USD Million (2018-2023)
  • Table 57. Japan Nano-drug, by Application USD Million (2018-2023)
  • Table 58. Japan Nano-drug, by Technology USD Million (2018-2023)
  • Table 59. Japan Nano-drug, by Product Type USD Million (2018-2023)
  • Table 60. India Nano-drug, by Type USD Million (2018-2023)
  • Table 61. India Nano-drug, by Application USD Million (2018-2023)
  • Table 62. India Nano-drug, by Technology USD Million (2018-2023)
  • Table 63. India Nano-drug, by Product Type USD Million (2018-2023)
  • Table 64. South Korea Nano-drug, by Type USD Million (2018-2023)
  • Table 65. South Korea Nano-drug, by Application USD Million (2018-2023)
  • Table 66. South Korea Nano-drug, by Technology USD Million (2018-2023)
  • Table 67. South Korea Nano-drug, by Product Type USD Million (2018-2023)
  • Table 68. Taiwan Nano-drug, by Type USD Million (2018-2023)
  • Table 69. Taiwan Nano-drug, by Application USD Million (2018-2023)
  • Table 70. Taiwan Nano-drug, by Technology USD Million (2018-2023)
  • Table 71. Taiwan Nano-drug, by Product Type USD Million (2018-2023)
  • Table 72. Australia Nano-drug, by Type USD Million (2018-2023)
  • Table 73. Australia Nano-drug, by Application USD Million (2018-2023)
  • Table 74. Australia Nano-drug, by Technology USD Million (2018-2023)
  • Table 75. Australia Nano-drug, by Product Type USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Nano-drug, by Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Nano-drug, by Application USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Nano-drug, by Technology USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Nano-drug, by Product Type USD Million (2018-2023)
  • Table 80. Europe Nano-drug, by Country USD Million (2018-2023)
  • Table 81. Europe Nano-drug, by Type USD Million (2018-2023)
  • Table 82. Europe Nano-drug, by Application USD Million (2018-2023)
  • Table 83. Europe Nano-drug, by Technology USD Million (2018-2023)
  • Table 84. Europe Nano-drug, by Product Type USD Million (2018-2023)
  • Table 85. Germany Nano-drug, by Type USD Million (2018-2023)
  • Table 86. Germany Nano-drug, by Application USD Million (2018-2023)
  • Table 87. Germany Nano-drug, by Technology USD Million (2018-2023)
  • Table 88. Germany Nano-drug, by Product Type USD Million (2018-2023)
  • Table 89. France Nano-drug, by Type USD Million (2018-2023)
  • Table 90. France Nano-drug, by Application USD Million (2018-2023)
  • Table 91. France Nano-drug, by Technology USD Million (2018-2023)
  • Table 92. France Nano-drug, by Product Type USD Million (2018-2023)
  • Table 93. Italy Nano-drug, by Type USD Million (2018-2023)
  • Table 94. Italy Nano-drug, by Application USD Million (2018-2023)
  • Table 95. Italy Nano-drug, by Technology USD Million (2018-2023)
  • Table 96. Italy Nano-drug, by Product Type USD Million (2018-2023)
  • Table 97. United Kingdom Nano-drug, by Type USD Million (2018-2023)
  • Table 98. United Kingdom Nano-drug, by Application USD Million (2018-2023)
  • Table 99. United Kingdom Nano-drug, by Technology USD Million (2018-2023)
  • Table 100. United Kingdom Nano-drug, by Product Type USD Million (2018-2023)
  • Table 101. Netherlands Nano-drug, by Type USD Million (2018-2023)
  • Table 102. Netherlands Nano-drug, by Application USD Million (2018-2023)
  • Table 103. Netherlands Nano-drug, by Technology USD Million (2018-2023)
  • Table 104. Netherlands Nano-drug, by Product Type USD Million (2018-2023)
  • Table 105. Rest of Europe Nano-drug, by Type USD Million (2018-2023)
  • Table 106. Rest of Europe Nano-drug, by Application USD Million (2018-2023)
  • Table 107. Rest of Europe Nano-drug, by Technology USD Million (2018-2023)
  • Table 108. Rest of Europe Nano-drug, by Product Type USD Million (2018-2023)
  • Table 109. MEA Nano-drug, by Country USD Million (2018-2023)
  • Table 110. MEA Nano-drug, by Type USD Million (2018-2023)
  • Table 111. MEA Nano-drug, by Application USD Million (2018-2023)
  • Table 112. MEA Nano-drug, by Technology USD Million (2018-2023)
  • Table 113. MEA Nano-drug, by Product Type USD Million (2018-2023)
  • Table 114. Middle East Nano-drug, by Type USD Million (2018-2023)
  • Table 115. Middle East Nano-drug, by Application USD Million (2018-2023)
  • Table 116. Middle East Nano-drug, by Technology USD Million (2018-2023)
  • Table 117. Middle East Nano-drug, by Product Type USD Million (2018-2023)
  • Table 118. Africa Nano-drug, by Type USD Million (2018-2023)
  • Table 119. Africa Nano-drug, by Application USD Million (2018-2023)
  • Table 120. Africa Nano-drug, by Technology USD Million (2018-2023)
  • Table 121. Africa Nano-drug, by Product Type USD Million (2018-2023)
  • Table 122. North America Nano-drug, by Country USD Million (2018-2023)
  • Table 123. North America Nano-drug, by Type USD Million (2018-2023)
  • Table 124. North America Nano-drug, by Application USD Million (2018-2023)
  • Table 125. North America Nano-drug, by Technology USD Million (2018-2023)
  • Table 126. North America Nano-drug, by Product Type USD Million (2018-2023)
  • Table 127. United States Nano-drug, by Type USD Million (2018-2023)
  • Table 128. United States Nano-drug, by Application USD Million (2018-2023)
  • Table 129. United States Nano-drug, by Technology USD Million (2018-2023)
  • Table 130. United States Nano-drug, by Product Type USD Million (2018-2023)
  • Table 131. Canada Nano-drug, by Type USD Million (2018-2023)
  • Table 132. Canada Nano-drug, by Application USD Million (2018-2023)
  • Table 133. Canada Nano-drug, by Technology USD Million (2018-2023)
  • Table 134. Canada Nano-drug, by Product Type USD Million (2018-2023)
  • Table 135. Mexico Nano-drug, by Type USD Million (2018-2023)
  • Table 136. Mexico Nano-drug, by Application USD Million (2018-2023)
  • Table 137. Mexico Nano-drug, by Technology USD Million (2018-2023)
  • Table 138. Mexico Nano-drug, by Product Type USD Million (2018-2023)
  • Table 139. Nano-drug Sales: by Type(K Tons)
  • Table 140. Nano-drug Sales Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region K Tons (2018-2023)
  • Table 141. Nano-drug Sales Nanoshells , by Region K Tons (2018-2023)
  • Table 142. Nano-drug Sales Nanotubes , by Region K Tons (2018-2023)
  • Table 143. Nano-drug Sales Nanodevices , by Region K Tons (2018-2023)
  • Table 144. Nano-drug Sales: by Application(K Tons)
  • Table 145. Nano-drug Sales Neurology , by Region K Tons (2018-2023)
  • Table 146. Nano-drug Sales Oncology , by Region K Tons (2018-2023)
  • Table 147. Nano-drug Sales Cardiovascular/Physiology , by Region K Tons (2018-2023)
  • Table 148. Nano-drug Sales Anti-inflammatory/Immunology , by Region K Tons (2018-2023)
  • Table 149. Nano-drug Sales Anti-infective , by Region K Tons (2018-2023)
  • Table 150. Nano-drug Sales Other , by Region K Tons (2018-2023)
  • Table 151. Nano-drug Sales: by Technology(K Tons)
  • Table 152. Nano-drug Sales Nanocrystals , by Region K Tons (2018-2023)
  • Table 153. Nano-drug Sales Nanoparticles , by Region K Tons (2018-2023)
  • Table 154. Nano-drug Sales Liposomes , by Region K Tons (2018-2023)
  • Table 155. Nano-drug Sales Micelles , by Region K Tons (2018-2023)
  • Table 156. Nano-drug Sales Others , by Region K Tons (2018-2023)
  • Table 157. Nano-drug Sales: by Type(K Tons)
  • Table 158. Nano-drug Sales Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region K Tons (2018-2023)
  • Table 159. Nano-drug Sales Nanoshells , by Region K Tons (2018-2023)
  • Table 160. Nano-drug Sales Nanotubes , by Region K Tons (2018-2023)
  • Table 161. Nano-drug Sales Nanodevices , by Region K Tons (2018-2023)
  • Table 162. Nano-drug Sales: by Product Type(K Tons)
  • Table 163. Nano-drug Sales Therapeutics , by Region K Tons (2018-2023)
  • Table 164. Nano-drug Sales Regenerative medicine , by Region K Tons (2018-2023)
  • Table 165. Nano-drug Sales In-vitro diagnostics , by Region K Tons (2018-2023)
  • Table 166. Nano-drug Sales In-vivo diagnostics , by Region K Tons (2018-2023)
  • Table 167. Nano-drug Sales Vaccines , by Region K Tons (2018-2023)
  • Table 168. South America Nano-drug Sales, by Country K Tons (2018-2023)
  • Table 169. South America Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 170. South America Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 171. South America Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 172. South America Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 173. Brazil Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 174. Brazil Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 175. Brazil Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 176. Brazil Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 177. Argentina Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 178. Argentina Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 179. Argentina Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 180. Argentina Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 181. Rest of South America Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 182. Rest of South America Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 183. Rest of South America Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 184. Rest of South America Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 185. Asia Pacific Nano-drug Sales, by Country K Tons (2018-2023)
  • Table 186. Asia Pacific Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 187. Asia Pacific Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 188. Asia Pacific Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 189. Asia Pacific Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 190. China Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 191. China Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 192. China Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 193. China Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 194. Japan Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 195. Japan Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 196. Japan Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 197. Japan Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 198. India Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 199. India Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 200. India Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 201. India Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 202. South Korea Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 203. South Korea Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 204. South Korea Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 205. South Korea Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 206. Taiwan Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 207. Taiwan Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 208. Taiwan Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 209. Taiwan Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 210. Australia Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 211. Australia Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 212. Australia Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 213. Australia Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 214. Rest of Asia-Pacific Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 215. Rest of Asia-Pacific Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 216. Rest of Asia-Pacific Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 217. Rest of Asia-Pacific Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 218. Europe Nano-drug Sales, by Country K Tons (2018-2023)
  • Table 219. Europe Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 220. Europe Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 221. Europe Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 222. Europe Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 223. Germany Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 224. Germany Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 225. Germany Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 226. Germany Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 227. France Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 228. France Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 229. France Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 230. France Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 231. Italy Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 232. Italy Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 233. Italy Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 234. Italy Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 235. United Kingdom Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 236. United Kingdom Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 237. United Kingdom Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 238. United Kingdom Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 239. Netherlands Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 240. Netherlands Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 241. Netherlands Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 242. Netherlands Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 243. Rest of Europe Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 244. Rest of Europe Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 245. Rest of Europe Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 246. Rest of Europe Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 247. MEA Nano-drug Sales, by Country K Tons (2018-2023)
  • Table 248. MEA Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 249. MEA Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 250. MEA Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 251. MEA Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 252. Middle East Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 253. Middle East Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 254. Middle East Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 255. Middle East Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 256. Africa Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 257. Africa Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 258. Africa Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 259. Africa Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 260. North America Nano-drug Sales, by Country K Tons (2018-2023)
  • Table 261. North America Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 262. North America Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 263. North America Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 264. North America Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 265. United States Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 266. United States Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 267. United States Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 268. United States Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 269. Canada Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 270. Canada Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 271. Canada Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 272. Canada Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 273. Mexico Nano-drug Sales, by Type K Tons (2018-2023)
  • Table 274. Mexico Nano-drug Sales, by Application K Tons (2018-2023)
  • Table 275. Mexico Nano-drug Sales, by Technology K Tons (2018-2023)
  • Table 276. Mexico Nano-drug Sales, by Product Type K Tons (2018-2023)
  • Table 277. Nano-drug: by Type(USD/Units)
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Company Basic Information, Sales Area and Its Competitors
  • Table 283. Company Basic Information, Sales Area and Its Competitors
  • Table 284. Company Basic Information, Sales Area and Its Competitors
  • Table 285. Company Basic Information, Sales Area and Its Competitors
  • Table 286. Company Basic Information, Sales Area and Its Competitors
  • Table 287. Company Basic Information, Sales Area and Its Competitors
  • Table 288. Company Basic Information, Sales Area and Its Competitors
  • Table 289. Company Basic Information, Sales Area and Its Competitors
  • Table 290. Company Basic Information, Sales Area and Its Competitors
  • Table 291. Company Basic Information, Sales Area and Its Competitors
  • Table 292. Company Basic Information, Sales Area and Its Competitors
  • Table 293. Company Basic Information, Sales Area and Its Competitors
  • Table 294. Company Basic Information, Sales Area and Its Competitors
  • Table 295. Company Basic Information, Sales Area and Its Competitors
  • Table 296. Nano-drug: by Type(USD Million)
  • Table 297. Nano-drug Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region USD Million (2025-2030)
  • Table 298. Nano-drug Nanoshells , by Region USD Million (2025-2030)
  • Table 299. Nano-drug Nanotubes , by Region USD Million (2025-2030)
  • Table 300. Nano-drug Nanodevices , by Region USD Million (2025-2030)
  • Table 301. Nano-drug: by Application(USD Million)
  • Table 302. Nano-drug Neurology , by Region USD Million (2025-2030)
  • Table 303. Nano-drug Oncology , by Region USD Million (2025-2030)
  • Table 304. Nano-drug Cardiovascular/Physiology , by Region USD Million (2025-2030)
  • Table 305. Nano-drug Anti-inflammatory/Immunology , by Region USD Million (2025-2030)
  • Table 306. Nano-drug Anti-infective , by Region USD Million (2025-2030)
  • Table 307. Nano-drug Other , by Region USD Million (2025-2030)
  • Table 308. Nano-drug: by Technology(USD Million)
  • Table 309. Nano-drug Nanocrystals , by Region USD Million (2025-2030)
  • Table 310. Nano-drug Nanoparticles , by Region USD Million (2025-2030)
  • Table 311. Nano-drug Liposomes , by Region USD Million (2025-2030)
  • Table 312. Nano-drug Micelles , by Region USD Million (2025-2030)
  • Table 313. Nano-drug Others , by Region USD Million (2025-2030)
  • Table 314. Nano-drug: by Type(USD Million)
  • Table 315. Nano-drug Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region USD Million (2025-2030)
  • Table 316. Nano-drug Nanoshells , by Region USD Million (2025-2030)
  • Table 317. Nano-drug Nanotubes , by Region USD Million (2025-2030)
  • Table 318. Nano-drug Nanodevices , by Region USD Million (2025-2030)
  • Table 319. Nano-drug: by Product Type(USD Million)
  • Table 320. Nano-drug Therapeutics , by Region USD Million (2025-2030)
  • Table 321. Nano-drug Regenerative medicine , by Region USD Million (2025-2030)
  • Table 322. Nano-drug In-vitro diagnostics , by Region USD Million (2025-2030)
  • Table 323. Nano-drug In-vivo diagnostics , by Region USD Million (2025-2030)
  • Table 324. Nano-drug Vaccines , by Region USD Million (2025-2030)
  • Table 325. South America Nano-drug, by Country USD Million (2025-2030)
  • Table 326. South America Nano-drug, by Type USD Million (2025-2030)
  • Table 327. South America Nano-drug, by Application USD Million (2025-2030)
  • Table 328. South America Nano-drug, by Technology USD Million (2025-2030)
  • Table 329. South America Nano-drug, by Product Type USD Million (2025-2030)
  • Table 330. Brazil Nano-drug, by Type USD Million (2025-2030)
  • Table 331. Brazil Nano-drug, by Application USD Million (2025-2030)
  • Table 332. Brazil Nano-drug, by Technology USD Million (2025-2030)
  • Table 333. Brazil Nano-drug, by Product Type USD Million (2025-2030)
  • Table 334. Argentina Nano-drug, by Type USD Million (2025-2030)
  • Table 335. Argentina Nano-drug, by Application USD Million (2025-2030)
  • Table 336. Argentina Nano-drug, by Technology USD Million (2025-2030)
  • Table 337. Argentina Nano-drug, by Product Type USD Million (2025-2030)
  • Table 338. Rest of South America Nano-drug, by Type USD Million (2025-2030)
  • Table 339. Rest of South America Nano-drug, by Application USD Million (2025-2030)
  • Table 340. Rest of South America Nano-drug, by Technology USD Million (2025-2030)
  • Table 341. Rest of South America Nano-drug, by Product Type USD Million (2025-2030)
  • Table 342. Asia Pacific Nano-drug, by Country USD Million (2025-2030)
  • Table 343. Asia Pacific Nano-drug, by Type USD Million (2025-2030)
  • Table 344. Asia Pacific Nano-drug, by Application USD Million (2025-2030)
  • Table 345. Asia Pacific Nano-drug, by Technology USD Million (2025-2030)
  • Table 346. Asia Pacific Nano-drug, by Product Type USD Million (2025-2030)
  • Table 347. China Nano-drug, by Type USD Million (2025-2030)
  • Table 348. China Nano-drug, by Application USD Million (2025-2030)
  • Table 349. China Nano-drug, by Technology USD Million (2025-2030)
  • Table 350. China Nano-drug, by Product Type USD Million (2025-2030)
  • Table 351. Japan Nano-drug, by Type USD Million (2025-2030)
  • Table 352. Japan Nano-drug, by Application USD Million (2025-2030)
  • Table 353. Japan Nano-drug, by Technology USD Million (2025-2030)
  • Table 354. Japan Nano-drug, by Product Type USD Million (2025-2030)
  • Table 355. India Nano-drug, by Type USD Million (2025-2030)
  • Table 356. India Nano-drug, by Application USD Million (2025-2030)
  • Table 357. India Nano-drug, by Technology USD Million (2025-2030)
  • Table 358. India Nano-drug, by Product Type USD Million (2025-2030)
  • Table 359. South Korea Nano-drug, by Type USD Million (2025-2030)
  • Table 360. South Korea Nano-drug, by Application USD Million (2025-2030)
  • Table 361. South Korea Nano-drug, by Technology USD Million (2025-2030)
  • Table 362. South Korea Nano-drug, by Product Type USD Million (2025-2030)
  • Table 363. Taiwan Nano-drug, by Type USD Million (2025-2030)
  • Table 364. Taiwan Nano-drug, by Application USD Million (2025-2030)
  • Table 365. Taiwan Nano-drug, by Technology USD Million (2025-2030)
  • Table 366. Taiwan Nano-drug, by Product Type USD Million (2025-2030)
  • Table 367. Australia Nano-drug, by Type USD Million (2025-2030)
  • Table 368. Australia Nano-drug, by Application USD Million (2025-2030)
  • Table 369. Australia Nano-drug, by Technology USD Million (2025-2030)
  • Table 370. Australia Nano-drug, by Product Type USD Million (2025-2030)
  • Table 371. Rest of Asia-Pacific Nano-drug, by Type USD Million (2025-2030)
  • Table 372. Rest of Asia-Pacific Nano-drug, by Application USD Million (2025-2030)
  • Table 373. Rest of Asia-Pacific Nano-drug, by Technology USD Million (2025-2030)
  • Table 374. Rest of Asia-Pacific Nano-drug, by Product Type USD Million (2025-2030)
  • Table 375. Europe Nano-drug, by Country USD Million (2025-2030)
  • Table 376. Europe Nano-drug, by Type USD Million (2025-2030)
  • Table 377. Europe Nano-drug, by Application USD Million (2025-2030)
  • Table 378. Europe Nano-drug, by Technology USD Million (2025-2030)
  • Table 379. Europe Nano-drug, by Product Type USD Million (2025-2030)
  • Table 380. Germany Nano-drug, by Type USD Million (2025-2030)
  • Table 381. Germany Nano-drug, by Application USD Million (2025-2030)
  • Table 382. Germany Nano-drug, by Technology USD Million (2025-2030)
  • Table 383. Germany Nano-drug, by Product Type USD Million (2025-2030)
  • Table 384. France Nano-drug, by Type USD Million (2025-2030)
  • Table 385. France Nano-drug, by Application USD Million (2025-2030)
  • Table 386. France Nano-drug, by Technology USD Million (2025-2030)
  • Table 387. France Nano-drug, by Product Type USD Million (2025-2030)
  • Table 388. Italy Nano-drug, by Type USD Million (2025-2030)
  • Table 389. Italy Nano-drug, by Application USD Million (2025-2030)
  • Table 390. Italy Nano-drug, by Technology USD Million (2025-2030)
  • Table 391. Italy Nano-drug, by Product Type USD Million (2025-2030)
  • Table 392. United Kingdom Nano-drug, by Type USD Million (2025-2030)
  • Table 393. United Kingdom Nano-drug, by Application USD Million (2025-2030)
  • Table 394. United Kingdom Nano-drug, by Technology USD Million (2025-2030)
  • Table 395. United Kingdom Nano-drug, by Product Type USD Million (2025-2030)
  • Table 396. Netherlands Nano-drug, by Type USD Million (2025-2030)
  • Table 397. Netherlands Nano-drug, by Application USD Million (2025-2030)
  • Table 398. Netherlands Nano-drug, by Technology USD Million (2025-2030)
  • Table 399. Netherlands Nano-drug, by Product Type USD Million (2025-2030)
  • Table 400. Rest of Europe Nano-drug, by Type USD Million (2025-2030)
  • Table 401. Rest of Europe Nano-drug, by Application USD Million (2025-2030)
  • Table 402. Rest of Europe Nano-drug, by Technology USD Million (2025-2030)
  • Table 403. Rest of Europe Nano-drug, by Product Type USD Million (2025-2030)
  • Table 404. MEA Nano-drug, by Country USD Million (2025-2030)
  • Table 405. MEA Nano-drug, by Type USD Million (2025-2030)
  • Table 406. MEA Nano-drug, by Application USD Million (2025-2030)
  • Table 407. MEA Nano-drug, by Technology USD Million (2025-2030)
  • Table 408. MEA Nano-drug, by Product Type USD Million (2025-2030)
  • Table 409. Middle East Nano-drug, by Type USD Million (2025-2030)
  • Table 410. Middle East Nano-drug, by Application USD Million (2025-2030)
  • Table 411. Middle East Nano-drug, by Technology USD Million (2025-2030)
  • Table 412. Middle East Nano-drug, by Product Type USD Million (2025-2030)
  • Table 413. Africa Nano-drug, by Type USD Million (2025-2030)
  • Table 414. Africa Nano-drug, by Application USD Million (2025-2030)
  • Table 415. Africa Nano-drug, by Technology USD Million (2025-2030)
  • Table 416. Africa Nano-drug, by Product Type USD Million (2025-2030)
  • Table 417. North America Nano-drug, by Country USD Million (2025-2030)
  • Table 418. North America Nano-drug, by Type USD Million (2025-2030)
  • Table 419. North America Nano-drug, by Application USD Million (2025-2030)
  • Table 420. North America Nano-drug, by Technology USD Million (2025-2030)
  • Table 421. North America Nano-drug, by Product Type USD Million (2025-2030)
  • Table 422. United States Nano-drug, by Type USD Million (2025-2030)
  • Table 423. United States Nano-drug, by Application USD Million (2025-2030)
  • Table 424. United States Nano-drug, by Technology USD Million (2025-2030)
  • Table 425. United States Nano-drug, by Product Type USD Million (2025-2030)
  • Table 426. Canada Nano-drug, by Type USD Million (2025-2030)
  • Table 427. Canada Nano-drug, by Application USD Million (2025-2030)
  • Table 428. Canada Nano-drug, by Technology USD Million (2025-2030)
  • Table 429. Canada Nano-drug, by Product Type USD Million (2025-2030)
  • Table 430. Mexico Nano-drug, by Type USD Million (2025-2030)
  • Table 431. Mexico Nano-drug, by Application USD Million (2025-2030)
  • Table 432. Mexico Nano-drug, by Technology USD Million (2025-2030)
  • Table 433. Mexico Nano-drug, by Product Type USD Million (2025-2030)
  • Table 434. Nano-drug Sales: by Type(K Tons)
  • Table 435. Nano-drug Sales Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region K Tons (2025-2030)
  • Table 436. Nano-drug Sales Nanoshells , by Region K Tons (2025-2030)
  • Table 437. Nano-drug Sales Nanotubes , by Region K Tons (2025-2030)
  • Table 438. Nano-drug Sales Nanodevices , by Region K Tons (2025-2030)
  • Table 439. Nano-drug Sales: by Application(K Tons)
  • Table 440. Nano-drug Sales Neurology , by Region K Tons (2025-2030)
  • Table 441. Nano-drug Sales Oncology , by Region K Tons (2025-2030)
  • Table 442. Nano-drug Sales Cardiovascular/Physiology , by Region K Tons (2025-2030)
  • Table 443. Nano-drug Sales Anti-inflammatory/Immunology , by Region K Tons (2025-2030)
  • Table 444. Nano-drug Sales Anti-infective , by Region K Tons (2025-2030)
  • Table 445. Nano-drug Sales Other , by Region K Tons (2025-2030)
  • Table 446. Nano-drug Sales: by Technology(K Tons)
  • Table 447. Nano-drug Sales Nanocrystals , by Region K Tons (2025-2030)
  • Table 448. Nano-drug Sales Nanoparticles , by Region K Tons (2025-2030)
  • Table 449. Nano-drug Sales Liposomes , by Region K Tons (2025-2030)
  • Table 450. Nano-drug Sales Micelles , by Region K Tons (2025-2030)
  • Table 451. Nano-drug Sales Others , by Region K Tons (2025-2030)
  • Table 452. Nano-drug Sales: by Type(K Tons)
  • Table 453. Nano-drug Sales Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & polymer-drug conjugates, Hydrogel nanoparticles, Dendrimers, Inorganic nanoparticles] , by Region K Tons (2025-2030)
  • Table 454. Nano-drug Sales Nanoshells , by Region K Tons (2025-2030)
  • Table 455. Nano-drug Sales Nanotubes , by Region K Tons (2025-2030)
  • Table 456. Nano-drug Sales Nanodevices , by Region K Tons (2025-2030)
  • Table 457. Nano-drug Sales: by Product Type(K Tons)
  • Table 458. Nano-drug Sales Therapeutics , by Region K Tons (2025-2030)
  • Table 459. Nano-drug Sales Regenerative medicine , by Region K Tons (2025-2030)
  • Table 460. Nano-drug Sales In-vitro diagnostics , by Region K Tons (2025-2030)
  • Table 461. Nano-drug Sales In-vivo diagnostics , by Region K Tons (2025-2030)
  • Table 462. Nano-drug Sales Vaccines , by Region K Tons (2025-2030)
  • Table 463. South America Nano-drug Sales, by Country K Tons (2025-2030)
  • Table 464. South America Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 465. South America Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 466. South America Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 467. South America Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 468. Brazil Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 469. Brazil Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 470. Brazil Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 471. Brazil Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 472. Argentina Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 473. Argentina Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 474. Argentina Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 475. Argentina Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 476. Rest of South America Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 477. Rest of South America Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 478. Rest of South America Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 479. Rest of South America Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 480. Asia Pacific Nano-drug Sales, by Country K Tons (2025-2030)
  • Table 481. Asia Pacific Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 482. Asia Pacific Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 483. Asia Pacific Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 484. Asia Pacific Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 485. China Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 486. China Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 487. China Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 488. China Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 489. Japan Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 490. Japan Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 491. Japan Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 492. Japan Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 493. India Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 494. India Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 495. India Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 496. India Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 497. South Korea Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 498. South Korea Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 499. South Korea Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 500. South Korea Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 501. Taiwan Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 502. Taiwan Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 503. Taiwan Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 504. Taiwan Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 505. Australia Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 506. Australia Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 507. Australia Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 508. Australia Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 509. Rest of Asia-Pacific Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 510. Rest of Asia-Pacific Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 511. Rest of Asia-Pacific Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 512. Rest of Asia-Pacific Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 513. Europe Nano-drug Sales, by Country K Tons (2025-2030)
  • Table 514. Europe Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 515. Europe Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 516. Europe Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 517. Europe Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 518. Germany Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 519. Germany Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 520. Germany Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 521. Germany Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 522. France Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 523. France Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 524. France Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 525. France Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 526. Italy Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 527. Italy Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 528. Italy Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 529. Italy Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 530. United Kingdom Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 531. United Kingdom Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 532. United Kingdom Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 533. United Kingdom Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 534. Netherlands Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 535. Netherlands Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 536. Netherlands Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 537. Netherlands Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 538. Rest of Europe Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 539. Rest of Europe Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 540. Rest of Europe Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 541. Rest of Europe Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 542. MEA Nano-drug Sales, by Country K Tons (2025-2030)
  • Table 543. MEA Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 544. MEA Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 545. MEA Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 546. MEA Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 547. Middle East Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 548. Middle East Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 549. Middle East Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 550. Middle East Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 551. Africa Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 552. Africa Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 553. Africa Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 554. Africa Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 555. North America Nano-drug Sales, by Country K Tons (2025-2030)
  • Table 556. North America Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 557. North America Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 558. North America Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 559. North America Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 560. United States Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 561. United States Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 562. United States Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 563. United States Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 564. Canada Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 565. Canada Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 566. Canada Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 567. Canada Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 568. Mexico Nano-drug Sales, by Type K Tons (2025-2030)
  • Table 569. Mexico Nano-drug Sales, by Application K Tons (2025-2030)
  • Table 570. Mexico Nano-drug Sales, by Technology K Tons (2025-2030)
  • Table 571. Mexico Nano-drug Sales, by Product Type K Tons (2025-2030)
  • Table 572. Nano-drug: by Type(USD/Units)
  • Table 573. Research Programs/Design for This Report
  • Table 574. Key Data Information from Secondary Sources
  • Table 575. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nano-drug: by Type USD Million (2018-2023)
  • Figure 5. Global Nano-drug: by Application USD Million (2018-2023)
  • Figure 6. Global Nano-drug: by Technology USD Million (2018-2023)
  • Figure 7. Global Nano-drug: by Type USD Million (2018-2023)
  • Figure 8. Global Nano-drug: by Product Type USD Million (2018-2023)
  • Figure 9. South America Nano-drug Share (%), by Country
  • Figure 10. Asia Pacific Nano-drug Share (%), by Country
  • Figure 11. Europe Nano-drug Share (%), by Country
  • Figure 12. MEA Nano-drug Share (%), by Country
  • Figure 13. North America Nano-drug Share (%), by Country
  • Figure 14. Global Nano-drug: by Type K Tons (2018-2023)
  • Figure 15. Global Nano-drug: by Application K Tons (2018-2023)
  • Figure 16. Global Nano-drug: by Technology K Tons (2018-2023)
  • Figure 17. Global Nano-drug: by Type K Tons (2018-2023)
  • Figure 18. Global Nano-drug: by Product Type K Tons (2018-2023)
  • Figure 19. South America Nano-drug Share (%), by Country
  • Figure 20. Asia Pacific Nano-drug Share (%), by Country
  • Figure 21. Europe Nano-drug Share (%), by Country
  • Figure 22. MEA Nano-drug Share (%), by Country
  • Figure 23. North America Nano-drug Share (%), by Country
  • Figure 24. Global Nano-drug: by Type USD/Units (2018-2023)
  • Figure 25. Global Nano-drug share by Players 2023 (%)
  • Figure 26. Global Nano-drug share by Players (Top 3) 2023(%)
  • Figure 27. Global Nano-drug share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2023
  • Figure 33. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 37. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 41. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi (France) Revenue: by Geography 2023
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 45. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 47. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 48. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 49. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 50. Celgene (United States) Revenue: by Geography 2023
  • Figure 51. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 52. Novavax (United States) Revenue: by Geography 2023
  • Figure 53. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 54. Stryker Corporation (United States) Revenue: by Geography 2023
  • Figure 55. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 56. Gilead Sciences (United States) Revenue: by Geography 2023
  • Figure 57. Samyang Biopharm (South Korea) Revenue, Net Income and Gross profit
  • Figure 58. Samyang Biopharm (South Korea) Revenue: by Geography 2023
  • Figure 59. Kaken Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 60. Kaken Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 61. Selecta Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 62. Selecta Biosciences (United States) Revenue: by Geography 2023
  • Figure 63. Par Pharmaceutical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 64. Par Pharmaceutical, Inc. (United States) Revenue: by Geography 2023
  • Figure 65. Global Nano-drug: by Type USD Million (2025-2030)
  • Figure 66. Global Nano-drug: by Application USD Million (2025-2030)
  • Figure 67. Global Nano-drug: by Technology USD Million (2025-2030)
  • Figure 68. Global Nano-drug: by Type USD Million (2025-2030)
  • Figure 69. Global Nano-drug: by Product Type USD Million (2025-2030)
  • Figure 70. South America Nano-drug Share (%), by Country
  • Figure 71. Asia Pacific Nano-drug Share (%), by Country
  • Figure 72. Europe Nano-drug Share (%), by Country
  • Figure 73. MEA Nano-drug Share (%), by Country
  • Figure 74. North America Nano-drug Share (%), by Country
  • Figure 75. Global Nano-drug: by Type K Tons (2025-2030)
  • Figure 76. Global Nano-drug: by Application K Tons (2025-2030)
  • Figure 77. Global Nano-drug: by Technology K Tons (2025-2030)
  • Figure 78. Global Nano-drug: by Type K Tons (2025-2030)
  • Figure 79. Global Nano-drug: by Product Type K Tons (2025-2030)
  • Figure 80. South America Nano-drug Share (%), by Country
  • Figure 81. Asia Pacific Nano-drug Share (%), by Country
  • Figure 82. Europe Nano-drug Share (%), by Country
  • Figure 83. MEA Nano-drug Share (%), by Country
  • Figure 84. North America Nano-drug Share (%), by Country
  • Figure 85. Global Nano-drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck & Co. (United States)
  • Pfizer (United States)
  • Novartis (Switzerland)
  • Abbott Laboratories (United States)
  • GlaxoSmithKline (United Kingdom)
  • Roche Holding AG (Switzerland)
  • Sanofi (France)
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • Johnson & Johnson (United States)
  • Celgene (United States)
  • Novavax (United States)
  • Stryker Corporation (United States)
  • Gilead Sciences (United States)
  • Samyang Biopharm (South Korea)
  • Kaken Pharmaceutical (Japan)
  • Selecta Biosciences (United States)
  • Par Pharmaceutical, Inc. (United States)
Additional players considered in the study are as follows:
Cerulean Pharma, Inc. (United States) , Navidea Biopharmaceuticals, Inc. (United States) , Chongqing LUMMY Pharmaceutical Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Apr 2024 234 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nano-drug Quantitative research analysis
Global Nano-drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Nano-drug market are Merck & Co. (United States), Pfizer (United States), Novartis (Switzerland), Abbott Laboratories (United States), GlaxoSmithKline (United Kingdom), Roche Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Celgene (United States), Novavax (United States), Stryker Corporation (United States), Gilead Sciences (United States), Samyang Biopharm (South Korea), Kaken Pharmaceutical (Japan), Selecta Biosciences (United States) and Par Pharmaceutical, Inc. (United States).
In this highly competitive & fast evolving Nano-drug industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective and Other are the potential customers of Nano-drug industry.
The Global Nano-drug market is expected to see a growth of 12.6% during projected year 2023 to 2030.

Know More About Global Nano-drug Report?

Have a Query? Click Here

Other Related Reports

Mice Model Comprehensive Study by Type (Inbred Mice, Outbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Conditioned/Surgically Modified Mice), Application (Cancer Research, Inflammation...
$ 3750
Protein Purification & Isolation Comprehensive Study by End Users (Hospitals and Diagnostic Centers, Contract Research Organization, Academic Medical Institutes, Pharmaceuticals & Biotechnology), Pro...
$ 3800
Biologics Safety Testing Comprehensive Study by Type (Endotoxin Tests, Sterility Tests, Cell Line Authentication and Characterization Tests, Bioburden Tests, Cell Line Authentication, Residual Host C...
$ 3750
Stem Cell Assay Comprehensive Study by Type (Viability/Cytotoxicity, Isolation & Purification, Cell Identification, Proliferation, Differentiation, Function, Apoptosis), Application (Regenerative Med...
$ 3750
Downstream Processing Comprehensive Study by Type (Chromatography Columns and Resins, Filters, Membrane Adsorbers, Single-use Products, Other Products (Consumables and Accessories)), Application (Mon...
$ 3750
Recombinant Protein Drugs Comprehensive Study by Application (Medicine, Research, Biotechnology, Others), Category (Protein, Monoclonal Antibody, Vaccine, Cytokines, Others) Players and Region - Glob...
$ 3500